Provided by Tiger Trade Technology Pte. Ltd.

Johnson & Johnson

264.74
-2.8300-1.06%
Pre-market: 264.39-0.3500-0.13%07:40 EDT
Volume:6.34M
Turnover:1.69B
Market Cap:637.84B
PE:30.66
High:268.48
Open:267.91
Low:264.51
Close:267.57
52wk High:281.07
52wk Low:182.94
Shares:2.41B
Float Shares:2.40B
Volume Ratio:1.06
T/O Rate:0.26%
Dividend:5.24
Dividend Rate:1.98%
EPS(TTM):8.64
EPS(LYR):11.03
ROE:25.74%
ROA:8.59%
PB:7.51
PE(LYR):23.99

Loading ...

Johnson & Johnson Says Subcutaneous Cancer Treatment Study Shows Low Rates Across Key Events, Discontinuation

MT Newswires Live
·
Sep 15

JNJ Reports Low Rates of Treatment-Related Events for Rybrevant Faspro Plus Lazcluze at Wclc 2026

Reuters
·
Sep 15

J&J - Fewer than 1% Discontinue Rybrevant Faspro Plus Lazcluze Due to Treatment-Related Events at One Year

THOMSON REUTERS
·
Sep 15

Contineum Therapeutics Says Phase 2 Major Depressive Disorder Study Fails to Meet Primary Efficacy Endpoint

MT Newswires Live
·
Sep 15

Medtronic PLC Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 15

Contineum Therapeutics Shares Fall After Drug Trial Missed Primary Endpoint

Dow Jones
·
Sep 15

Contineum, J&J's Depression Drug Fails to Meet Mid-Stage Trial Goal

Reuters
·
Sep 15

Contineum Therapeutics, - Johnson & Johnson Continues to Evaluate Trial Data for Jnj-5120/Pipe-307

THOMSON REUTERS
·
Sep 15

Sector Update: Healthcare Stocks Rise Premarket Monday

MT Newswires Live
·
Sep 14

U.S. Stocks on the MOVE-US Energy Stocks, Baldwin, Johnson & Johnson

Reuters
·
Sep 14

J&J - Jnj Reports Rybrevant Plus Chemotherapy Extends Pfs2 by 10.8 Months in Nsclc

THOMSON REUTERS
·
Sep 14

Johnson & Johnson’s Rybrevant® (Amivantamab-Vmjw) Plus Chemotherapy Delivers Longest Reported Median Overall Survival in Egfr Exon 20 Insertion Mutation-Positive Lung Cancer

THOMSON REUTERS
·
Sep 14

J&J - Jnj Reports no New Safety Signals for Rybrevant Plus Chemotherapy in Nsclc Study

THOMSON REUTERS
·
Sep 14

Potential Buyer Emerges for Johnson & Johnson's Orthopedics Unit

Deep News
·
Sep 14

Johnson & Johnson reports PAPILLON study meets primary endpoint

TIPRANKS
·
Sep 14

Market Chatter: Apollo Global in Talks to Buy J&J Orthopedics Unit for $20 Billion

MT Newswires Live
·
Sep 14

Nanobiotix announces updated safety, efficacy data from JNJ-1900 study

TIPRANKS
·
Sep 14

Johnson & Johnson Says Lung Cancer Drug Combination Extends Median Survival to Over 34 Months

MT Newswires Live
·
Sep 14

J&J Shares up 1.2% Premarket After Report Co's Orthopedics Unit Draws Apollo Interest in Potential $20 Bln Deal

THOMSON REUTERS
·
Sep 14

Dow Jones Top Company Headlines at 1 am ET: Biggest AI Rivals Agree They Need to Slow it Down | Amazon ...

Dow Jones
·
Sep 14